Novo Nordisk
Novo Nordisk

Novo Nordisk

Pharmaceuticals
WebsiteInvestor RelationsSEC
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

$172.4B

Market Cap • 10/23/2026

1931

(95 years)

Founded

1981

(45 years ago)

IPO

NYSE

Listing Exchange

Flag of Denmark

Denmark

Country

Valuation

P/B

5,1

P/S

3,4

P/EBITDA

6,6

P/OCF

8,4

P/FCF

14,6

P/E

9,6

BVPS

7,7

EPS

4,1

Market Cap

Market Cap

172,4B

EV

186,9B

EV/Revenue

3,7

EV/EBITDA

7,1

EV/EBIT

8,5

Payout

Dividend Per Share

1,8

Dividend Yield

4,6%

Buyback Yield

0,5%

Total Yield

5,1%

Dividend Yield 5Y

3,2%

Payout

44,1%

Retained Earnings

34,2B

Profitability

Gross Margin

80,6%

EBITDA Margin

51,3%

EBIT Margin

43,1%

Net Margin

35,3%

D&A/EBITDA

0%

R&D/Revenue

17,6%

Capex/Revenue

16,9%

Capex/D&A

206,6%

Capex/OCF

42,3%

SBC/OCF

—

% PPE

39%

% Goodwill

3,3%

ROE

60%

ROIC

30,3%

Growth

CAGR Revenue 5Y

19,8%

CAGR Op. Income 5Y

20,8%

CAGR Net Income 5Y

20,7%

CAGR EPS 5Y

21,6%

CAGR OCF 5Y

17,4%

Leverage

N.D./EBITDA

0,6

Debt/Equity

0%

Current Ratio

0,9

Quick Ratio

0,6

Interest Coverage

9146,9%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium